General Information of Drug Off-Target (DOT) (ID: OTQ9XX72)

DOT Name Histone H2B type 1-H (H2BC9)
Synonyms H2B-clustered histone 9; Histone H2B.j; H2B/j
Gene Name H2BC9
Related Disease
Advanced cancer ( )
UniProt ID
H2B1H_HUMAN
3D Structure
Download
2D Sequence (FASTA)
Download
3D Structure (PDB)
Download
Pfam ID
PF00125
Sequence
MPDPAKSAPAPKKGSKKAVTKAQKKDGKKRKRSRKESYSVYVYKVLKQVHPDTGISSKAM
GIMNSFVNDIFERIAGEASRLAHYNKRSTITSREIQTAVRLLLPGELAKHAVSEGTKAVT
KYTSSK
Function
Core component of nucleosome. Nucleosomes wrap and compact DNA into chromatin, limiting DNA accessibility to the cellular machineries which require DNA as a template. Histones thereby play a central role in transcription regulation, DNA repair, DNA replication and chromosomal stability. DNA accessibility is regulated via a complex set of post-translational modifications of histones, also called histone code, and nucleosome remodeling.
KEGG Pathway
Neutrophil extracellular trap formation (hsa04613 )
Alcoholism (hsa05034 )
Viral carcinogenesis (hsa05203 )
Systemic lupus erythematosus (hsa05322 )
Reactome Pathway
Cleavage of the damaged pyrimidine (R-HSA-110329 )
Recognition and association of DNA glycosylase with site containing an affected purine (R-HSA-110330 )
Cleavage of the damaged purine (R-HSA-110331 )
Meiotic synapsis (R-HSA-1221632 )
Packaging Of Telomere Ends (R-HSA-171306 )
Pre-NOTCH Transcription and Translation (R-HSA-1912408 )
Formation of the beta-catenin (R-HSA-201722 )
PRC2 methylates histones and DNA (R-HSA-212300 )
Condensation of Prophase Chromosomes (R-HSA-2299718 )
Oxidative Stress Induced Senescence (R-HSA-2559580 )
Senescence-Associated Secretory Phenotype (SASP) (R-HSA-2559582 )
DNA Damage/Telomere Stress Induced Senescence (R-HSA-2559586 )
HDACs deacetylate histones (R-HSA-3214815 )
HATs acetylate histones (R-HSA-3214847 )
SIRT1 negatively regulates rRNA expression (R-HSA-427359 )
ERCC6 (CSB) and EHMT2 (G9a) positively regulate rRNA expression (R-HSA-427389 )
NoRC negatively regulates rRNA expression (R-HSA-427413 )
B-WICH complex positively regulates rRNA expression (R-HSA-5250924 )
DNA methylation (R-HSA-5334118 )
Transcriptional regulation by small RNAs (R-HSA-5578749 )
Activation of anterior HOX genes in hindbrain development during early embryogenesis (R-HSA-5617472 )
Activated PKN1 stimulates transcription of AR (androgen receptor) regulated genes KLK2 and KLK3 (R-HSA-5625886 )
Ub-specific processing proteases (R-HSA-5689880 )
Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks (R-HSA-5693565 )
Nonhomologous End-Joining (NHEJ) (R-HSA-5693571 )
Processing of DNA double-strand break ends (R-HSA-5693607 )
Deposition of new CENPA-containing nucleosomes at the centromere (R-HSA-606279 )
Assembly of the ORC complex at the origin of replication (R-HSA-68616 )
G2/M DNA damage checkpoint (R-HSA-69473 )
RNA Polymerase I Promoter Opening (R-HSA-73728 )
RNA Polymerase I Promoter Escape (R-HSA-73772 )
E3 ubiquitin ligases ubiquitinate target proteins (R-HSA-8866654 )
RUNX1 regulates genes involved in megakaryocyte differentiation and platelet function (R-HSA-8936459 )
RUNX1 regulates transcription of genes involved in differentiation of HSCs (R-HSA-8939236 )
Estrogen-dependent gene expression (R-HSA-9018519 )
Meiotic recombination (R-HSA-912446 )
HCMV Early Events (R-HSA-9609690 )
HCMV Late Events (R-HSA-9610379 )
Transcriptional regulation of granulopoiesis (R-HSA-9616222 )
Inhibition of DNA recombination at telomere (R-HSA-9670095 )
Defective pyroptosis (R-HSA-9710421 )
Amyloid fiber formation (R-HSA-977225 )
Chromatin modifications during the maternal to zygotic transition (MZT) (R-HSA-9821002 )
Replacement of protamines by nucleosomes in the male pronucleus (R-HSA-9821993 )
Recognition and association of DNA glycosylase with site containing an affected pyrimidine (R-HSA-110328 )

Molecular Interaction Atlas (MIA) of This DOT

1 Disease(s) Related to This DOT
Disease Name Disease ID Evidence Level Mode of Inheritance REF
Advanced cancer DISAT1Z9 Strong Biomarker [1]
------------------------------------------------------------------------------------
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This DOT
21 Drug(s) Affected the Gene/Protein Processing of This DOT
Drug Name Drug ID Highest Status Interaction REF
Valproate DMCFE9I Approved Valproate decreases the expression of Histone H2B type 1-H (H2BC9). [2]
Tretinoin DM49DUI Approved Tretinoin decreases the expression of Histone H2B type 1-H (H2BC9). [3]
Acetaminophen DMUIE76 Approved Acetaminophen increases the expression of Histone H2B type 1-H (H2BC9). [4]
Doxorubicin DMVP5YE Approved Doxorubicin decreases the expression of Histone H2B type 1-H (H2BC9). [5]
Cupric Sulfate DMP0NFQ Approved Cupric Sulfate increases the expression of Histone H2B type 1-H (H2BC9). [6]
Estradiol DMUNTE3 Approved Estradiol affects the expression of Histone H2B type 1-H (H2BC9). [7]
Arsenic trioxide DM61TA4 Approved Arsenic trioxide decreases the expression of Histone H2B type 1-H (H2BC9). [8]
Methotrexate DM2TEOL Approved Methotrexate decreases the expression of Histone H2B type 1-H (H2BC9). [9]
Menadione DMSJDTY Approved Menadione affects the expression of Histone H2B type 1-H (H2BC9). [10]
Isotretinoin DM4QTBN Approved Isotretinoin decreases the expression of Histone H2B type 1-H (H2BC9). [11]
Troglitazone DM3VFPD Approved Troglitazone decreases the expression of Histone H2B type 1-H (H2BC9). [12]
Dasatinib DMJV2EK Approved Dasatinib decreases the expression of Histone H2B type 1-H (H2BC9). [13]
Lucanthone DMZLBUO Approved Lucanthone decreases the expression of Histone H2B type 1-H (H2BC9). [14]
Berberine DMC5Q8X Phase 4 Berberine decreases the expression of Histone H2B type 1-H (H2BC9). [15]
PEITC DMOMN31 Phase 2 PEITC decreases the expression of Histone H2B type 1-H (H2BC9). [16]
(+)-JQ1 DM1CZSJ Phase 1 (+)-JQ1 increases the expression of Histone H2B type 1-H (H2BC9). [18]
PMID28460551-Compound-2 DM4DOUB Patented PMID28460551-Compound-2 decreases the expression of Histone H2B type 1-H (H2BC9). [19]
Bisphenol A DM2ZLD7 Investigative Bisphenol A decreases the expression of Histone H2B type 1-H (H2BC9). [21]
Milchsaure DM462BT Investigative Milchsaure increases the expression of Histone H2B type 1-H (H2BC9). [22]
Coumestrol DM40TBU Investigative Coumestrol decreases the expression of Histone H2B type 1-H (H2BC9). [23]
Paraquat DMR8O3X Investigative Paraquat decreases the expression of Histone H2B type 1-H (H2BC9). [24]
------------------------------------------------------------------------------------
⏷ Show the Full List of 21 Drug(s)
2 Drug(s) Affected the Post-Translational Modifications of This DOT
Drug Name Drug ID Highest Status Interaction REF
Benzo(a)pyrene DMN7J43 Phase 1 Benzo(a)pyrene decreases the methylation of Histone H2B type 1-H (H2BC9). [17]
PMID28870136-Compound-52 DMFDERP Patented PMID28870136-Compound-52 decreases the phosphorylation of Histone H2B type 1-H (H2BC9). [20]
------------------------------------------------------------------------------------

References

1 iTRAQ-based quantitative proteomic analysis provides insight for molecular mechanism of neuroticism.Clin Proteomics. 2019 Nov 8;16:38. doi: 10.1186/s12014-019-9259-8. eCollection 2019.
2 Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.
3 Development of a neural teratogenicity test based on human embryonic stem cells: response to retinoic acid exposure. Toxicol Sci. 2011 Dec;124(2):370-7.
4 Gene expression analysis of precision-cut human liver slices indicates stable expression of ADME-Tox related genes. Toxicol Appl Pharmacol. 2011 May 15;253(1):57-69.
5 Bringing in vitro analysis closer to in vivo: studying doxorubicin toxicity and associated mechanisms in 3D human microtissues with PBPK-based dose modelling. Toxicol Lett. 2018 Sep 15;294:184-192.
6 Physiological and toxicological transcriptome changes in HepG2 cells exposed to copper. Physiol Genomics. 2009 Aug 7;38(3):386-401.
7 Identification of novel low-dose bisphenol a targets in human foreskin fibroblast cells derived from hypospadias patients. PLoS One. 2012;7(5):e36711. doi: 10.1371/journal.pone.0036711. Epub 2012 May 4.
8 Identification of transcriptome signatures and biomarkers specific for potential developmental toxicants inhibiting human neural crest cell migration. Arch Toxicol. 2016 Jan;90(1):159-80.
9 Methotrexate modulates folate phenotype and inflammatory profile in EA.hy 926 cells. Eur J Pharmacol. 2014 Jun 5;732:60-7.
10 Global gene expression analysis reveals differences in cellular responses to hydroxyl- and superoxide anion radical-induced oxidative stress in caco-2 cells. Toxicol Sci. 2010 Apr;114(2):193-203. doi: 10.1093/toxsci/kfp309. Epub 2009 Dec 31.
11 Temporal changes in gene expression in the skin of patients treated with isotretinoin provide insight into its mechanism of action. Dermatoendocrinol. 2009 May;1(3):177-87.
12 Effects of ciglitazone and troglitazone on the proliferation of human stomach cancer cells. World J Gastroenterol. 2009 Jan 21;15(3):310-20.
13 Dasatinib reverses cancer-associated fibroblasts (CAFs) from primary lung carcinomas to a phenotype comparable to that of normal fibroblasts. Mol Cancer. 2010 Jun 27;9:168.
14 Lucanthone is a novel inhibitor of autophagy that induces cathepsin D-mediated apoptosis. J Biol Chem. 2011 Feb 25;286(8):6602-13.
15 Berberine acts as a putative epigenetic modulator by affecting the histone code. Toxicol In Vitro. 2016 Oct;36:10-17. doi: 10.1016/j.tiv.2016.06.004. Epub 2016 Jun 13.
16 Phenethyl isothiocyanate alters the gene expression and the levels of protein associated with cell cycle regulation in human glioblastoma GBM 8401 cells. Environ Toxicol. 2017 Jan;32(1):176-187.
17 Air pollution and DNA methylation alterations in lung cancer: A systematic and comparative study. Oncotarget. 2017 Jan 3;8(1):1369-1391. doi: 10.18632/oncotarget.13622.
18 Synergistic activity of BET protein antagonist-based combinations in mantle cell lymphoma cells sensitive or resistant to ibrutinib. Blood. 2015 Sep 24;126(13):1565-74.
19 Cell-based two-dimensional morphological assessment system to predict cancer drug-induced cardiotoxicity using human induced pluripotent stem cell-derived cardiomyocytes. Toxicol Appl Pharmacol. 2019 Nov 15;383:114761. doi: 10.1016/j.taap.2019.114761. Epub 2019 Sep 15.
20 Quantitative phosphoproteomics reveal cellular responses from caffeine, coumarin and quercetin in treated HepG2 cells. Toxicol Appl Pharmacol. 2022 Aug 15;449:116110. doi: 10.1016/j.taap.2022.116110. Epub 2022 Jun 7.
21 Bisphenol A induces DSB-ATM-p53 signaling leading to cell cycle arrest, senescence, autophagy, stress response, and estrogen release in human fetal lung fibroblasts. Arch Toxicol. 2018 Apr;92(4):1453-1469.
22 Transcriptional profiling of lactic acid treated reconstructed human epidermis reveals pathways underlying stinging and itch. Toxicol In Vitro. 2019 Jun;57:164-173.
23 Pleiotropic combinatorial transcriptomes of human breast cancer cells exposed to mixtures of dietary phytoestrogens. Food Chem Toxicol. 2009 Apr;47(4):787-95.
24 An in vitro strategy using multiple human induced pluripotent stem cell-derived models to assess the toxicity of chemicals: A case study on paraquat. Toxicol In Vitro. 2022 Jun;81:105333. doi: 10.1016/j.tiv.2022.105333. Epub 2022 Feb 16.